Gilead Sciences Inc

The article highlights three companies with strong cash flow generation as attractive investment opportunities for 2026: Qualcomm with $12.8 billion in free cash flow (up 15% YoY), Gilead Sciences with nearly $4 billion in free cash flow and strong HIV medication sales, and Exxon Mobil with $14.8 billion in operating cash flow. All three offer co...

Gilead Sciences agreed to acquire Repare Therapeutics' polymerase theta (Polθ) ATPase inhibitor RP-3467 for up to $30 million ($25 million upfront plus $5 million upon technology transfer completion). The deal increases Repare's cash balance, raising the estimated cash payment to shareholders to approximately $2.20 per share. RPTX shares surged ...

Nurix Therapeutics reported promising Phase 1 trial results for bexobrutideg, an investigational drug for relapsed or refractory chronic lymphocytic leukemia, showing an 83% objective response rate and a median progression-free survival of 22.1 months.

Commodore Capital fully exited its position in Scholar Rock, selling approximately 1.5 million shares in Q3, representing a $51 million transaction. The biotech company is preparing to resubmit its apitegromab biologics license application after a previous FDA rejection.

Gilead Sciences (GILD) closed the most recent trading day at $69.61, moving -1.58% from the previous trading session.